Human MCL1 blocking peptide

Name: Human MCL1 blocking peptide
SKU: CDBP1841
Rating: 5 (1 reviews)

Synthetic Human MCL1 blocking peptide for Apuri, BL, ELISA

Write a review

COA

SDS

Datasheet

Product Overview

Blocking/Immunizing peptide for anti-MCL1 antibody

Target

MCL1

Nature

Synthetic

Tag/Conjugate

Unconjugated

Application Notes

For in vitro research use only. Not intended for any diagnostic or therapeutic purpose. Not for human or animal consumption.

Format

Lyophilized powder

Preservative

None

Storage

Shipped at ambient temperature, store at -20°C.

Gene ID

4170

UniProt ID

Q07820

Antigen Description

This gene encodes an anti-apoptotic protein, which is a member of the Bcl-2 family. Alternative splicing results in multiple transcript variants. The longest gene product (isoform 1) enhances cell survival by inhibiting apoptosis while the alternatively spliced shorter gene products (isoform 2 and isoform 3) promote apoptosis and are death-inducing. [provided by RefSeq, Oct 2010]

Function

BH3 domain binding; protein binding; protein channel activity; protein heterodimerization activity;

Synonyms

MCL1; myeloid cell leukemia sequence 1 (BCL2-related); induced myeloid leukemia cell differentiation protein Mcl-1; BCL2L3; Mcl 1; bcl-2-like protein 3; myeloid cell leukemia ES; bcl-2-related protein EAT/mcl1; TM; EAT; MCL1L; MCL1S; Mcl-1; MCL1-ES; bcl2-L-3; mcl1/EAT; MGC1839; MGC104264;

Citations

Have you cited CDBP1841 in a publication? Let us know and earn a reward for your research.

Product Name	Cat. No.	Applications	Host Species	Datasheet	Price	Add to Basket

Product Name	Cat. No.	Applications	Host Species	Datasheet	Price	Add to Basket

Datasheet

Certificate of Analysis

Safety Data Sheet

Customer Reviews

Write a review

Targeting CDK9 for treatment of colorectal cancer

MOLECULAR ONCOLOGY

Authors: Rahaman, Muhammed H.; Lam, Frankie; Zhong, Longjin; Teo, Theodosia; Adams, Julian; Yu, Mingfeng; Milne, Robert W.; Pepper, Chris; Lokman, Noor A.; Ricciardelli, Carmela; Oehler, Martin K.; Wang, Shudong

Abstract

Colorectal cancer (CRC) remains one of the most lethal human malignancies, and pursuit of new therapeutic targets for treatment has been a major research focus. Cyclin-dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment. CDKI-73, one of the most potent and pharmacologically superior CDK9 inhibitors, has demonstrated excellent anti-tumour efficacy against several types of cancers. In this study, we evaluated its therapeutic potential against CRC. CDKI-73 elicited high cytotoxicity against all colon cancer cell lines tested. Cell cycle and apoptosis analysis in HCT 116 and HT29 cells revealed that CDKI-73 induced cell death without accumulation of DNA at any phase of the cell cycle. Moreover, it caused depolarisation of mitochondrial membrane, leading to caspase-independent apoptosis. Knockdown by shRNA demonstrated the CDK9-targeted mechanism of CDKI-73, which also affected the Mnk/eIF4E signalling axis. In addition, RT-qPCR analysis showed that CDKI-73 down-regulated multiple pro-survival factors at the mRNA level. Its in vivo anti-tumour efficacy was further evaluated in Balb/c nude mice bearing HCT 116 xenograft tumours. CDKI-73 significantly inhibited tumour growth (***P < 0.001) without overt toxicity. Analysis of the tumour tissues collected from the xenografted animals confirmed that the in vivo anti-tumour efficacy was associated with CDK9 targeting of CDKI-73. Overall, this study provides compelling evidence that CDKI-73 is a promising drug candidate for treating colorectal cancer.

RNPS1 inhibition aggravates ischemic brain injury and promotes neuronal death

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Authors: Zhang, Zhi; Guo, Mengdi; Liu, Ying; Liu, Pinyi; Cao, Xiang; Xu, Yun; Zhu, Xiaolei

Abstract

RNA-binding protein with serine-rich domain 1 (RNPS1) is essential for modulating mRNA metabolism, but its role in ischemic stroke is unknown. In this study, we found that RNPS1 expression was significantly up-regulated in the brains of ischemic stroke mice and primary cortical neurons after oxygen-glucose deprivation (OGD) treatment. Knockdown of RNPS1 significantly aggravated ischemic brain injury after middle cerebral artery occlusion (MCAO) and promoted neuronal death. In addition, knockdown of RNPS1 exacerbated ischemia induced neuronal apoptosis, and downregulated the expression of anti-apoptotic proteins Bcl-xL and Mcl-1. Our study suggested that RNPS1 might be a potential therapeutic target for alleviating neuronal death in ischemic stroke. (C) 2019 Elsevier Inc. All rights reserved.